Article Information
History
- February 10, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Teresa Maria Rosaria Noviello1,2,#,
- Anna Maria Di Giacomo3,4,5,#,
- Francesca Pia Caruso1,2,
- Alessia Covre4,
- Giovanni Scala1,
- Maria Claudia Costa1,2,
- Sandra Coral4,
- Wolf H. Fridman6,7,8,
- Catherine Sautès-Fridman6,7,8,
- Roberta Mortarini9,
- Silvia Brich10,
- Giancarlo Pruneri10,
- Elena Simonetti3,
- Maria Fortunata Lofiego4,
- Davide Bedognetti11,
- Andrea Anichini9,
- Michele Maio3,4,5,#,*,
- Michele Ceccarelli1,2,# and
- the EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators
- 1Department of Electrical Engineering and Information Technology (DIETI), University of Naples “Federico II”, Naples, Italy
- 2BIOGEM Institute of Molecular Biology and Genetics, Ariano Irpino, Italy
- 3Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy
- 4University of Siena, Siena, Italy
- 5NIBIT Foundation Onlus, Italy
- 6INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team Cancer, Immune Control and Escape, Paris, France
- 7University Paris Descartes Paris 5, Sorbonne Paris Cite, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
- 8Sorbonne University, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France
- 9Human Tumors Immunobiology Unit, Dept. of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 10Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 11Cancer Program, Human Immunology Department, Research Branch, Sidra Medicine, Doha, Qatar
- ↵*Corresponding author; email: maio{at}unisi.it
↵# Contributed equally
Posted February 10, 2023.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
